Overview

Building on expertise across stem cell biology, synthetic biology, and molecular genetics, we have developed a platform identifying cancer stem cell specific regulatory circuits. These can be deployed in gene therapies enabling highly selective delivery of anti-cancer payloads to simultaneously disrupt multiple pathways needed to sustain tumour growth and stimulate immune responses. We are building a pipeline of therapeutics to address the unmet need of various solid tumours. Backed by SV Health Investors, a leading transatlantic life sciences & healthcare investor with over $3 billion in capital commitments, Cellinta has raised capital from the Impact Medicine Fund, which invests in precision medicine therapeutics in areas of high unmet need. We are hiring! Reach out to learn more about opportunities to join our team.